Vol. 4 No. 11 (2024)
Reimbursement Recommendations

Avapritinib (Ayvakyt)

Published November 19, 2024

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Ayvakyt be reimbursed by public drug plans for the treatment of adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL), only if certain conditions are met.
  • Ayvakyt should only be covered to treat adult patients with AdvSM who have a diagnosis of ASM, SM-AHN, or MCL based on WHO criteria and have an Eastern Cooperative Oncology Group (ECOG) performance status score (which estimates patients’ ability to perform activities of daily living) of 0 (no symptoms, fully active) to 3 (symptomatic, confined to bed or chair 50% or more of waking hours). Patients with AdvSM who have low platelet counts are not eligible for Ayvakyt.
  • Ayvakyt should only be reimbursed if prescribed by medical teams with access to expertise in the diagnosis, treatment, and response evaluation of patients with AdvSM. It should only be reimbursed if the cost of Ayvakyt is reduced and the economic feasibility of Ayvakyt is addressed.